The ATP-binding cassette transporters and their implication in drug disposition: A special look at the heart

Pharmacological Reviews

Volumn 58, Issue 2, 2006, Pages 244-258

  Couture, Lucie ^a,b   Nash, John A ^b   Turgeon, Jacques ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; ABC TRANSPORTER; ADEFOVIR; AMIODARONE; ANTHRACYCLINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CISPLATIN; CLARITHROMYCIN; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ERYTHROMYCIN; ETOPOSIDE; GLYCOPROTEIN P; GREPAFLOXACIN; IDARUBICIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 6; PACLITAXEL; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOTOXICITY; CELL MEMBRANE TRANSPORT; CONGESTIVE HEART FAILURE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SENSITIVITY; DRUG TISSUE LEVEL; DRUG TRANSPORT; GENETIC POLYMORPHISM; HEART MUSCLE INJURY; HUMAN; HYPOTENSION; KNOCKOUT MOUSE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; QT PROLONGATION; REVIEW; TUMOR CELL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CALCIUM CHANNEL BLOCKERS; CARDIOMYOPATHIES; DOXORUBICIN; HEART; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYOCARDIUM; P-GLYCOPROTEINS; VERAPAMIL;

EID: 33646741238     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.58.2.7     Document Type: Review

References (166)

1. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, and Schinkel AH (2003) Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 63:1339-1344.
2. Aronica A, Gorter JA, Redeker S, van Vliet EA, Ramkema M, Scheffer GL, Scheper RJ, van der Valk P, Leenstra S, Baayen JC, et al. (2005) Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46:849-857.
3. Baas F and Borst P (1988) The tissue dependent expression of hamster P-glycoprotein genes. FEBS Lett 229:329-332.
4. Beaulieu E, Demeule M, Ghitescu L, and Béliveau R (1997) P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 326:539-544.
5. Belinsky MG, Bain LJ, Balsara BB, Testa JR, and Kruh GD (1998) Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J Natl Cancer Inst 90:1735-1741.
6. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, and Kruh GD (2002) Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 62:6172-6177.
7. Belinsky MG and Kruh GD (1999) MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver. Br J Cancer 80:1342-1349.
8. Bellamy WT, Peng YM, Odeleye A, Ellsworth L, Xu MJ, Grogan TM, and Weinstein RS (1995) Cardiotoxicity in the SCID mouse following administration of doxorubicin and cyclosporin A. Anticancer Drugs 6:736-743.
9. Bera TK, Iavarone C, Kumar V, Lee S, Lee B, and Pastan I (2002) MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc Natl Acad Sci USA 99:6997-7002.
10. Bera TK, Lee S, Salvatore G, Lee B, and Pastan I (2001) MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol Med 7:509-516.
11. Bergen AA, Plomp AS, Schuurman EJ, Terry S, Breuning M, Dauwerse H, Swart J, Kool M, van Soest S, Baas F, et al. (2000) Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet 25:228-231.
12. Brown PC, Thorgeirsson SS, and Silverman JA (1993) Cloning and regulation of the rat mdr2 gene. Nucleic Acids Res 21:3885-3891.
13. Cárcel-Trullols J, Torres-Molina F, Araico A, Saadeddin A, and Peris JE (2004) Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. Cancer Chemother Pharmacol 54:153-160.
14. 3H]daunomycin and MDR reversing agents. Anticancer Drugs 7:833-837.
15. Chang G (2003) Structure of MsbA from Vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation. J Mol Biol 330:419-430.
16. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, and Roninson IB (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389.
17. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, and Kruh GD (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62:3144-3150.
18. Cherrington NJ, Hartley DP, Li N, Johnson DR, and Klaassen CD (2002) Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2 and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 300:97-104.
19. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Wash DC) 258:1650-1654.
20. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, and Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910.
21. Colombo T, Gonzalez Paz O, and D'Incalci M (1996a) Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Br J Cancer 73:866-871.
22. Colombo T, Gonzalez Paz O, Zucchetti M, Maneo A, Sessa C, Goldhirsch A, and D'Incalci M (1996b) Paclitaxel induces significant changes in epidoxorubicin distribution in mice. Ann Oncol 7:801-805.
23. Colombo T, Zucchetti M, and D'Incalci M (1994) Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther 269:22-27.
24. Cox DS, Scott KR, Gao H, and Eddington ND (2002) Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. J Pharmacol Exp Ther 302:1096-1104.
25. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, and Housman DE (1989) The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9:1346-1350.
26. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, and Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929-937.
27. Dano K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323:466-483.
28. Dazert P, Meissner K, Vogelgesang S, Heydrich B, Eckel L, Bohm M, Warzok R, Kerb R, Brinkmann U, Schaeffeler E, et al. (2003) Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. Am J Pathol 163:1567-1577.
29. de Graaf D, Sharma RC, Mechetner EB, Schimke RT, and Roninson IB (1996) P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci USA 93:1238-1242.
30. de Lannoy IA and Silverman M (1992) The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 189:551-557.
31. Dean M, Hamon Y, and Chimini G (2001) The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42:1007-1017.
32. Dell'Acqua G, Polishchuck R, Fallon JT, and Gordon JW (1999) Cardiac resistance to Adriamycin in transgenic mice expressing a rat α-cardiac myosin heavy chain/human multiple drug resistance 1 fusion gene. Hum Gene Ther 10:1269-1279.
33. Devault A and Gros P (1990) Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 10:1652-1663.
34. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
35. Estevez MD, Wolf A, and Schramm U (2000) Effect of PSC 833, verapamil and amiodarone on Adriamycin toxicity in cultured rat cardiomyocytes. Toxicol In Vitro 14:17-23.
36. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, and Borst P (2000) Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 83:375-383.
37. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, et al. (2002) Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36.
38. Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, and Scheper RJ (1996) Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237-1247.
39. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, and Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269.
40. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, and Schrenk D (2000) The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157:1575-1580.
41. Furuya KN, Gebhardt R, Schuetz EG, and Schuetz JD (1994) Isolation of rat pgp3 cDNA: evidence for gender and zonal regulation of expression in the liver. Biochim Biophys Acta 1219:636-644.
42. Ghosh S, Ting S, Lau H, Pulinilkunnil T, An D, Qi D, Abrahani MA, and Rodrigues B (2004) Increased efflux of glutathione conjugate in acutely diabetic cardiomyocytes. Can J Physiol Pharmacol 82:879-887.
43. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, et al. (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699.
44. Goldschmidt N, Azaz-Livshits T, Gotsman, Nir-Paz R, Ben-Yehuda A, and Muszkat M (2001) Compound cardiac toxicity of oral erythromycin and verapamil. Ann Pharmacother 35:1396-1399.
45. Gonzalez O, Colombo T, De Fusco M, Imperatori L, Zucchetti M, and D'Incalci M (1995) Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother Pharmacol 36:335-340.
46. Gramatte T and Oertel R (1999) Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 66:239-245.
47. Granzotto M, Drigo I, Candussio L, Rosati A, Bartoli F, Giraldi T, and Decorti G (2004) Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells. Cancer Lett 205:107-115.
48. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, and Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Investig 104:147-153.
49. Gros P, Croop J, and Housman D (1986) Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47:371-380.
50. Gros P, Raymond M, Bell J, and Housman D (1988) Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol 8:2770-2778.
51. Hagen SG, Monroe DG, Dean DM, and Sanders MM (2000) Repression of chick multidrug resistance-associated protein 1 (chMRP1) gene expression by estrogen. Gene 257:243-249.
52. Haimeur A, Conseil G, Deeley RG, and Cole SP (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5:21-53.
53. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, and Kaufmann SH (1992) Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52:2268-2278.
54. Higgins CF, Hiles ID, Salmond GP, Gill DR, Downie JA, Evans IJ, Holland IB, Gray L, Buckel SD, Bell AW, et al. (1986) A family of related ATP-binding subunits coupled to many distinct biological processes in bacteria. Nature 323:448-450.
55. Hill BT, Deuchars K, Hosking LK, Ling V, and Whelan RD (1990) Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. J Natl Cancer Inst 82:607-612.
56. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
57. Holzinger A, Kammerer S, Berger J, and Roscher AA (1997) cDNA cloning and mRNA expression of the human adrenoleukodystrophy related protein (ALDRP), a peroxisomal ABC transporter. Biochem Biophys Res Commun 239:261-264.
58. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, and Jansen G (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532-2535.
59. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, and Kruh GD (2004) Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 64:4927-4930.
60. Hrycyna CA, Ramachandra M, Germann UA, Cheng PW, Pastan I, and Gottesman MM (1999) Both ATP sites of human P-glycoprotein are essential but not symmetric. Biochemistry 38:13887-13899.
61. Hsu SI, Lothstein L, and Horwitz SB (1989) Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells: evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes. J Biol Chem 264:12053-12062.
62. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, and Schinkel AH (2002) Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors and transport can be enhanced by other drugs. AIDS 16:2295-2301.
63. Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard RE, and Higgins CF (1990) Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature (Lond) 346:362-365.
64. Jetté L, Beaulieu E, Leclerc JM, and Beliveau R (1996) Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 270:F756-F765.
65. Jetté L, Pouliot JF, Murphy GF, and Beliveau R (1995) Isoform I (mdr3) is the major form of P-glycoprotein expressed in mouse brain capillaries: evidence for cross-reactivity of antibody C219 with an unrelated protein. Biochem J 305:761-766.
66. Jones K, Hoggard PG, Sales SD, Khoo S, Davey R, and Back DJ (2001) Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 15:675-681.
67. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
68. Kaeser YA, Brunner F, Drewe J, and Haefeli WE (1998) Severe hypotension and bradycardia associated with verapamil and clarithromycin. Am J Health Syst Pharm 55:2417-2418.
69. Kaminski WE, Wenzel JJ, Piehler A, Langmann T, and Schmitz G (2001) ABCA6, a novel a subclass ABC transporter. Biochem Biophys Res Commun 285:1295-1301.
70. Kang W and Weiss M (2001) Influence of P-glycoprotein modulators on cardiac uptake, metabolism and effects of idarubicin. Pharm Res (NY) 18:1535-1541.
71. Kao HH, Huang JD, and Chang MS (2002) cDNA cloning and genomic organization of the murine MRP7, a new ATP-binding cassette transporter. Gene 286:299-306.
72. Karlsson J, Kuo SM, Ziemniak J, and Artursson P (1993) Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 110:1009-1016.
73. Kartner N, Shales M, Riordan JR, and Ling V (1983) Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res 43:4413-4419.
74. 4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett 456:327-331.
75. Kim RB (2002) Drugs as P-glycoprotein substrates, inhibitors and inducers. Drug Metab Rev 34:47-54.
76. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Investig 101:289-294.
77. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (NY) 16:408-414.
78. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, and Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537-3547.
79. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, et al. (1999) MRP3 an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96:6914-6919.
80. Kubo Y, Sekiya S, Ohigashi M, Takenaka C, Tamura K, Nada S, Nishi T, Yamamoto A, and Yamaguchi A (2005) ABCA5 resides in lysosomes and ABCA5 knockout mice develop lysosomal disease-like symptoms. Mol Cell Biol 25:4138-4149.
81. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, and Schuetz JD (2000) Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol 57:24-35.
82. Lee K, Belinsky MG, Bell DW, Testa JR, and Kruh GD (1998) Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. Cancer Res 58:2741-2747.
83. Lee K, Klein-Szanto AJ, and Kruh GD (2000) Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 92:1934-1940.
84. Liu B, Sun D, Xia W, Hung MC, and Yu D (1997) Cross-reactivity of C219 antip170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1). J Natl Cancer Inst 89:1524-1529.
85. Locher KP and Borths E (2004) ABC transporter architecture and mechanism: implications from the crystal structures of BtuCD and BtuF. FEBS Lett 564:264-268.
86. Locher KP, Lee AT, and Rees DC (2002) The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science (Wash DC) 296:1091-1098.
87. Lowes S and Simmons NL (2002) Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 135:1263-1275.
88. Magnarin M, Morelli M, Rosati A, Bartoli F, Candussio L, Giraldi T, and Decorti G (2004) Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells. Eur J Pharmacol 483:19-28.
89. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
90. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, and Schellens JH (1999) Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59:4559-4563.
91. Martin CM, Meeson AP, Robertson SM, Hawke TJ, Richardson JA, Bates S, Goetsch SC, Gallardo TD, and Garry DJ (2004) Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Dev Biol 265:262-275.
92. Meissner K, Heydrich B, Jedlitschky G, Meyer zu Schwabedissen H, Mosyagin I, Dazert P, Eckel L, Vogelgesang S, Warzok RW, Bohm M, et al. (2006) The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. J Histochem Cytochem 54:215-221.
93. Meissner K, Jedlitschky G, Meyer zu Schwabedissen H, Dazert P, Eckel L, Vogelgesang S, Warzok RW, Bohm M, Lehmann C, Wendt M, et al. (2004) Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 14:381-385.
94. Meissner K, Sperker B, Karsten C, zu Schwabedissen HM, Seeland U, Bohm M, Bien S, Dazert P, Kunert-Keil C, Vogelgesang S, et al. (2002) Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J Histochem Cytochem 50:1351-1356.
95. Miller DS (2001) Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther 299:567-574.
96. Muramatsu T, Johnson DR, Finch RA, Johnson LK, Leffert JJ, Lin ZP, Pizzorno G, and Sartorelli AC (2004) Age-related differences in vincristine toxicity and biodistribution in wild-type and transporter-deficient mice. Oncol Res 14:331-343.
97. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, and Tsuji A (2001) Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. J Pharm Pharmacol 53:699-709.
98. Ng WF, Sarangi F, Zastawny RL, Veinot-Drebot L, and Ling V (1989) Identification of members of the P-glycoprotein multigene family. Mol Cell Biol 9:1224-1232.
99. Nishimura M, Naito S, and Yokoi T (2004) Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab Pharmacokinet 19:135-149.
100. Orr GA, Verdier-Pinard P, McDaid H, and Horwitz SB (2003) Mechanisms of Taxol resistance related to microtubules. Oncogene 22:7280-7295.
101. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, and Willingham MC (1988) A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85:4486-4490.
102. Pauli-Magnus C, Feiner J, Brett C, Lin E, and Kroetz DL (2003) No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther 74:487-498.
103. Pavelic ZP, Reising J, Pavelic L, Kelley DJ, Stambrook PJ, and Gluckman JL (1993) Detection of P-glycoprotein with four monoclonal antibodies in normal and tumor tissues. Arch Otolaryngol Head Neck Surg 119:753-757.
104. Peters WH and Roelofs HM (1992) Biochemical characterization of resistance to mitoxantrone and Adriamycin in Caco-2 human colon adenocarcinoma cells: a possible role for glutathione S-transferases. Cancer Res 52:1886-1890.
105. Piehler A, Kaminski WE, Wenzel JJ, Langmann T, and Schmitz G (2002) Molecular structure of a novel cholesterol-responsive A subclass ABC transporter, ABCA9. Biochem Biophys Res Commun 295:408-416.
106. Reyes CL and Chang G (2005) Structure of the ABC transporter MsbA in complex with ADP·vanadate and lipopolysaccharide. Science (Wash DC) 308:1028-1031.
107. Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, and Pastan I (1986) Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83:4538-4542.
108. Rosati A, Maniori S, Decorti G, Candussio L, Giraldi T, and Bartoli F (2003) Physiological regulation of P-glycoprotein, MRP1, MRP2 and cytochrome P450 3A2 during rat ontogeny. Dev Growth Differ 45:377-387.
109. Santostasi G, Kutty RK, and Krishna G (1991) Increased toxicity of anthracycline antibiotics induced by calcium entry blockers in cultured cardiomyocytes. Toxicol Appl Pharmacol 108:140-149.
110. Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, and Sugiyama Y (2004) Differential involvement of multidrug resistance-associated protein 1 and p-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. J Pharmacol Exp Ther 310:648-655.
111. Schaub TP, Kartenbeck J, Konig J, Vogel O, Witzgall R, Kriz W, and Keppler D (1997) Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. J Am Soc Nephrol 8:1213-1221.
112. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
113. Schinkel AH, Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Investig 97:2517-2524.
114. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, and Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J Clin Investig 96:1698-1705.
115. Schinkel AH (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8:161-170.
116. Schneider E and Hunke S (1998) ATP-binding-cassette (ABC) transport systems: functional and structural aspects of the ATP-hydrolyzing subunits/domains. FEMS Microbiol Rev 22:1-20.
117. Schuetz EG, Yasuda K, Arimori K, and Schuetz JD (1998) Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch Biochem Biophys 350:340-347.
118. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, and Fridland A (1999) MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5:1048-1051.
119. Schwab M, Eichelbaum M, and Fromm MF (2003) Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43:285-307.
120. Sharp SY, Smith V, Hobbs S, and Kelland LR (1998) Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. Br J Cancer 78:175-180.
121. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, and Cascorbi I (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72:572-583.
122. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P, Burk O, Decker J, Alken P, et al. (2002) Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 13:1847-1854.
123. Sims JJ, Neudeck BL, Loeb JM, and Wiegert NA (2004) Tachycardia-induced heart failure does not alter myocardial P-glycoprotein expression. Pharmacotherapy 24:1-7.
124. Smit JJ, Schinkel AH, Mol CA, Majoor D, Mooi WJ, Jongsma AP, Lincke CR, and Borst P (1994) Tissue distribution of the human MDR3 P-glycoprotein. Lab Investig 71:638-649.
125. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, et al. (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75:451-462.
126. Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G, Varadi A, Sarkadi B, and Borst P (2000) MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 275:23530-23539.
127. Solbach TF, Konig J, Fromm MF, and Zolk O (2006) ATP-binding cassette transporters in the heart. Trends Cardiovasc Med 16:7-15.
128. Soldner A, Benet LZ, Mutschler E, and Christians U (2000) Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol 129:1235-1243.
129. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
130. Sridhar R, Dwivedi C, Anderson J, Baker PB, Sharma HM, Desai P, and Engineer FN (1992) Effects of verapamil on the acute toxicity of doxorubicin in vivo. J Natl Cancer Inst 84:1653-1660.
131. Steenbergen JA and Stauffer VL (1998) Potential macrolide interaction with verapamil. Ann Pharmacother 32:387-388.
132. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, and Meier PJ (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422-430.
133. St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, Meier PJ, and Marin JJ (2000) Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol 279:R1495-R1503.
134. Stride BD, Valdimarsson G, Gerlach JH, Wilson GM, Cole SP, and Deeley RG (1996) Structure and expression of the messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter. Mol Pharmacol 49:962-971.
135. Sugawara I, Akiyama S, Scheper RJ, and Itoyama S (1997) Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett 112:23-31.
136. Takada Y, Yamada K, Taguchi Y, Kino K, Matsuo M, Tucker SJ, Komano T, Amachi T, and Ueda K (1998) Non-equivalent cooperation between the two nucleotide-binding folds of P-glycoprotein. Biochim Biophys Acta 1373:131-136.
137. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, and Murakami T (1998) Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 358:289-294.
138. Tamai I, Yamashita J, Kido Y, Ohnari A, Sai Y, Shima Y, Naruhashi K, Koizumi S, and Tsuji A (2000) Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther 295:146-152.
139. Teeter LD, Becker FF, Chisari FV, Li DJ, and Kuo MT (1990) Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol 10:5728-5735.
140. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1989) Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37:159-164.
141. Tirona RG and Kim RB (2002) Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliv Rev 54:1343-1352.
142. Török M, Gutmann H, Fricker G, and Drewe J (1999) Sister of P-glycoprotein expression in different tissues. Biochem Pharmacol 57:833-835.
143. Tsuruoka S, Ishibashi K, Yamamoto H, Wakaumi M, Suzuki M, Schwartz GJ, Imai M, and Fujimura A (2002) Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun 298:41-45.
144. Ueda K, Cardarelli C, Gottesman MM, and Pastan I (1987) Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 84:3004-3008.
145. Urbatsch IL, Beaudet L, Carrier I, and Gros P (1998) Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites. Biochemistry 37:4592-4602.
146. van Asperen J, van Tellingen O, Schinkel AH, and Beijnen JH (1999) Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein. J Pharmacol Exp Ther 289:329-333.
147. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, and van Tellingen O (1996) Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice. J Natl Cancer Inst 88:994-999.
148. Van der Bliek AM, Baas F, Ten Houte de Lange T, Kooiman PM, Van der Velde-Koerts T, and Borst P (1987) The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO (Eur Mol Biol Organ) J 6:3325-3331.
149. van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ, Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJ, Pinedo HM, et al. (1990) Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol 1:56-64.
150. van Kalken C, Giaccone G, van der Valk P, Kuiper CM, Hadisaputro MM, Bosma SA, Scheper RJ, Meijer CJ, and Pinedo HM (1992) Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am J Pathol 141:1063-1072.
151. Verschraagen M, Koks CH, Schellens JH, and Beijnen JH (1999) P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 40:301-306.
152. Volk EL, Farley KM, Wu Y, Li F, Robey RW, and Schneider E (2002) Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 62:5035-5040.
153. Volk EL and Schneider E (2003) Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538-5543.
154. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, and Armstrong VW (2001) No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 47:1048-1052.
155. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, and Inui K (1998) Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 64:123-128.
156. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, and Baba M (2003) Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol 63:65-72.
157. Wenzel JJ, Kaminski WE, Piehler A, Heimerl S, Langmann T, and Schmitz G (2003) ABCA10, a novel cholesterol-regulated ABCA6-like ABC transporter. Biochem Biophys Res Commun 306:1089-1098.
158. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, et al. (2000) Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 68:345-355.
159. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, Beijnen JH, van der Valk M, Krimpenfort P, and Borst P (1997) Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 3:1275-1279.
160. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, et al. (2000) Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 97:7476-7481.
161. Woodahl EL and Ho RJ (2004) The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 5:11-19.
162. Zelcer N, Saeki T, Reid G, Beijnen JH, and Borst P (2001) Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276:46400-46407.
163. Zeng H, Bain LJ, Belinsky MG, and Kruh GD (1999) Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 59:5964-5967.
164. Zhang S, Zhou Z, Gong Q, Makielski JC, and January CT (1999) Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84:989-998.
165. Zhang Y and Berger SA (2003) Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo. Cancer Chemother Pharmacol 51:407-414.
166. + channels expressed in Xenopus oocytes. Am J Physiol 272:H1309-H1314.